Portal de Periódicos da CAPES

Intravenous Bolus Topotecan in Patients with Myelodysplastic Syndrome

2001; Taylor & Francis; Volume: 42; Issue: 5 Linguagem: Inglês

10.3109/10428190109097715

1042-8194

Karen Seiter, Delong Liu, Eric J. Feldman, Ahmad Daniyal Siddiqui, Albert Hoang, Paul Baskind, Ram Kancherla, Tauseef Ahmed,

Neutropenia and Cancer Infections

We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.